Funding Will Support Development of 4C Medical's Transcatheter Technology for Mitral Regurgitation


July 19, 2017—4C Medical Technologies, Inc., a Minnesota-based company focused on the development of minimally invasive therapies for structural heart disease, announced funding to support the continued development of its transcatheter technology for the treatment of mitral regurgitation. The device is designed to preserve the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology.

The company stated that this financing will be used to finalize the design of the technology, which will be evaluated in a planned early feasibility study in the United States, and possibly Japan, to achieve first-in-human implants.

The gross proceeds of approximately $9 million were raised via a private placement of unsecured convertible promissory notes. The financing was led by an investment of $3.5 million by Anges Québec, the largest angel network in Canada.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.